Reneo Pharmaceuticals logo — company profile

Reneo Pharmaceuticals

Founded 2014 United States Irvine, United States 16 employees Post Ipo Equity Total: $220.00M Biotechnology, Pharmaceutical

General Information

Company Name Reneo Pharmaceuticals
Founded Year 2014
Location United States Irvine, United States +1
Founders / Decision Makers
Team member
Employees 16
Industries Biotechnology, Pharmaceutical
Funding Stage Post Ipo Equity
Social

Get notified when Reneo Pharmaceuticals moves

Funding, new markets, leadership changes, hiring surges — one e-mail, only when something happens.

Free · no account needed

About Reneo Pharmaceuticals

Reneo Pharmaceuticals is a clinical-stage pharmaceutical company founded in 2014 and based in the United States. The company is dedicated to developing and commercializing therapies for patients with rare genetic mitochondrial diseases. They focus on addressing the inability of mitochondria to produce adenosine triphosphate (ATP). Reneo's lead product candidate, mavodelpar (REN001), functions as a potent and selective agonist of the peroxisome proliferator-activated receptor delta (PPARδ). Clinical studies have shown that mavodelpar can increase the transcription of genes involved in mitochondrial function and fatty acid oxidation, potentially stimulating the production of new mitochondria. Reneo Pharmaceuticals received a significant $55.00M Post-IPO Equity investment on 03 May 2023. The investors involved in this last investment round were not specified. For more detailed information, visit reneopharma.com. Please note that Reneo's communications on LinkedIn are targeted at U.S. audiences exclusively. You can find their Digital Media Guidelines here: https://reneopharma.com/digital-media-community-guidelines/.

Funding Rounds & Investors (4)

View All
Funding Stage Amount Investors Lead Investors Date
Post-IPO Equity •••••• - 03 May 2023
Post-IPO Secondary •••••• - 01 May 2022
Series B •••••• 10
Investor Investor Investor Investor Investor Investor Investor Investor Investor
•••• ••••
09 Dec 2020
Series A •••••• - 20 May 2019

Reneo Pharmaceuticals Alternatives & Competitors

Reneo Pharmaceuticals vs
Kindred
Kindred Australia

Real estate, recreated.

30 employees
Prop Tech, Real Estate
Reneo Pharmaceuticals vs

ENCLOSURES OF TECHNOLOGY

7 employees
Manufacturing
Reneo Pharmaceuticals vs

Transforming Power Into Success

47 employees
Energy, Manufacturing

FAQ About Reneo Pharmaceuticals

Reneo Pharmaceuticals is now OnKure Therapeutics, Inc.!
Reneo Pharmaceuticals was founded in 2014.
Reneo Pharmaceuticals is headquartered in Irvine, United States.
Reneo Pharmaceuticals operates in the following industries: Biotechnology, Pharmaceutical.
Reneo Pharmaceuticals has approximately 16 employees.
Reneo Pharmaceuticals has completed 4 funding rounds, raising a total of $220.00M. The latest funding stage is Post Ipo Equity.
Top alternatives and competitors to Reneo Pharmaceuticals include Kindred, ATP - Cabinets & Racks, ASP Equipment GmbH, Goshen Central School District, Association for Mental Health and Wellness. These companies operate in related industries and serve comparable markets. You can compare them side by side on Bounce Watch.
Reneo Pharmaceuticals and Kindred are both companies in similar industries. Compare their funding, team size, growth signals, and market position on Bounce Watch to see which one fits your needs.

Don't just browse. Track.

Signal Tracker monitors Reneo Pharmaceuticals and millions of companies for funding rounds, hiring surges, product changes, and 40+ signal types — so you never miss an opportunity.

One analytics cookie (Google Analytics). Cookie Policy